Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, explains the implications of the longer-term follow-up of venetoclax in combination with the chemotherapy regimen cladribine, high-dose cytarabine, idarubicin (CLIA) and how age is a factor when considering chemotherapy options.
Longer-term outcomes seem to continue showing really encouraging results for the use of venetoclax in combination with the chemotherapy regimen cladribine, high-dose cytarabine, idarubicin (CLIA) in patients with newly-diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), said Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center.
Transcript
Were there any differences in results due to the longer-term follow-up in this study?
We're doing 2 things here. We have accrued more patients onto this study than per our last publication or our last presentation. So, we have more patients on the study today than we had in our publication or at the last time that we presented this at [the American Society of Hematology Annual Meeting & Exposition].
In addition, we have longer follow-up, so we have more patients and longer follow-up for especially the patients that had been on the study previously. The activity of the regimen is really confirmed with the additional patients. So, the response rate and how deep the responses are have been confirmed with the enrollment of more patients onto this study. That was really encouraging to see.
The longer-term outcomes seem to continue to show really encouraging results. We're not seeing many late relapses, or many late treatment failures on this study. Many of the earlier findings that we had shown before are really continuing to hold up at this later time point.
Based on these findings, are there any implications for older patients?
I think the first thing that needs to be done for anybody that's seeing these patients is that determination of whether they're eligible to receive intensive chemotherapy. The distinction is a lot [about] chronological age, but there are certainly patients that are young enough, just by the age cutoff, to have received intensive chemotherapy, but they may have other conditions that would make it such that intensive chemotherapy is not a good option. Any of those patients, either because of age or other comorbidities, I would say that this is not a regimen that would be applicable to them. In general, for the older patients or for the patients that are younger but are not eligible for intensive chemotherapy, this would not be a regimen that we should, at this time, use in those patients.
The other study does that. I think we have other regimens at MD Anderson that we're investigating, whereby we're hoping to improve the outcomes for those patients that are either older, or those that are ineligible for intensive chemotherapy.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More